CEL-SCI Receives Croatian Government Approval to Commence Phase III Clinical Trial of Multikine in Head and Neck Cancer

- CEL-SCI Corporation CVM announced today that it has received approval from the Health Protection Administration, Ministry of Health, of the Croatian Republic to begin enrollment of subjects into the Phase III clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection). Croatia is the ninth country into which CEL-SCI has expanded its global Phase III trial. The trial is expected to be conducted in about 100 clinical centers worldwide. CEL-SCI expects to enroll approximately 40 patients in Croatia through four clinical centers. CEL-SCI plans to accelerate enrollment in its Phase III clinical trial for Multikine by adding a large number of clinical centers in the eight countries where approval to start See full press release